



Investor Presentation


3Q 2020

GENESIS
Robotic Magnetic Navigation



FORWARD LOOKING STATEMENT

During the course of this presentation, the Company may make projections and other forward-looking statements regarding future events or the future financial performance of the Company, including without limitation, statements regarding future operating results, growth opportunities and other statements that refer to Stereotaxis' plans, prospects, expectations, strategies, intentions and beliefs. These statements are subject to many risks and uncertainties that could cause actual results to differ materially from expectations. For a detailed discussion of risks and uncertainties that affect the Company's business and qualify the forward-looking statements made in this presentation, we refer you to the Company's periodic and other public filings filed with the SEC, including the most recently filed Forms 8-K, 10-Q and 10-K. The Company's projections and forward-looking statements are based on factors that are subject to change and therefore these statements speak only as of the date they are given. The Company assumes no obligation to update any projections or forward-looking statements. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities. Such an offer or solicitation, if made, will only be made pursuant to an offering memorandum and definitive subscription documents.



Global Leader in Endovascular Robotics Focused on Treating Cardiac Arrhythmias

Extensive Presence

300+ Physicians

100+ Active Systems

20+ Countries

Validated & Protected

100,000+ Procedures

400+ Publications

100+ Issued Patents

Attractive Market

\$5B+ Existing Market

10%+ Annual Growth

Unique Robotic Solution

Financial Highlights*

\$26M Revenue

90% Recurring Revenue

80% Gross Margin


\$44M Cash

No Debt


Near Breakeven

* Income statement data reflects trailing four quarter results through 2Q2020 and is approximate for presentation purposes. Balance sheet approximate as of 2Q2020.

FOCUSED ON ENDOVASCULAR



Surgical Progress: Less Invasive. Less Risk. Improved Patient Care. Expanded Access to Care.



ROBOTICS TRANSFORMING SURGERY




Open Surgery



- >800 Installed Systems
- >100,000 Procedures/Year
- \$1.65 Billion Acquisition in 2013
- ~\$100 Million Revenue in 2013



- >200 Installed Systems
- >10,000 Procedures/Year
- \$1.65 Billion Acquisition in 2017
- ~\$65 Million Revenue in 2017



Laparoscopic Surgery



- >5,000 Installed Systems
- >1,000,000 Procedures/Year
- >\$60 Billion Valuation
- >\$4 Billion Revenue



- \$3.4+ Billion Acquisitions in 2019
- Negligible Revenue when Acquired



Endovascular Surgery




Many Others Competing or Investing to Compete:



UNMET NEEDS WE ADDRESS

Traditional Endovascular Surgery is Widely Utilized...



...but Entails Inherent Limitations, Challenges & Risks:

1

Limited Precision, Stability & Reach

Manipulation of the tip of a manual catheter relies on force being translated the length of the catheter

2

Rigid Catheter

Required rigidity of a manual catheter with inherent safety risks for patients

3

Radiation Exposure

Reliance on fluoroscopy for visualization places patients, physicians and staff at risk

4

Complex Procedures

Procedures require extensive training and outcomes are operator dependent

ROBOTIC MAGNETIC NAVIGATION

Direct catheter tip control using magnetic fields enables:

1mm Precision
Tip Stability
Extended Reach
Atraumatic Catheter
Radiation Protection
Intuitive Navigation

Robotic Magnetic Navigation System

External computer-controlled permanent magnets create a magnetic field within which a catheter with a magnetic tip can be precisely maneuvered.

Disposable & Magnetic Catheter

A disposable device advances and retracts a catheter with a magnetic tip.

Physician Cockpit

Physician sits at a computer control station, views procedure data on a large HD monitor, and uses a mouse/joystick to operate.

PLATFORM FOCUSED ON ARRHYTHMIAS

Arrhythmias

are

conditions in which the heart beats with an irregular or abnormal rhythm

Widespread

Tens of Millions of Arrhythmia Patients Globally

>10-15% Prevalence in Elderly Population

Growing Rapidly

Demographics:
Increases with Age & Obesity

Diagnosis:
Improved Diagnostic Technology

Serious

5x Higher Risk of Stroke from AF
3x Higher Risk of Heart Failure

>300,000 US Deaths/Year from VF
Lead Cause of Sudden Cardiac Death

**Cardiac Ablation,
A Leading Therapy**


**Stereotaxis,
A Differentiated
Competitor**

Catheter Ablation emerging as a leading therapy for arrhythmias vs pharma or CRM implants

>1,000,000 catheter cardiac ablation procedures per year globally

>\$5B market growing >10%/Year

Consistent long-term growth driven by clinical evidence, demographic trends and improved technology



IMPROVED OUTCOMES

72%

Fewer Major Complications

6-8%

Improved ST & LT Efficacy

36%

Less Radiation Exposure



BENEFITS: PHYSICIANS

OCCUPATIONAL SAFETY

Risk of the Cath Lab:

85%

Left vs Right Sided
Brain Tumors



50%

Cataracts



49%

Orthopedic Injury



2.9X

Increased Infertility



*Operate Seated, Unscrubbed, and Outside of
Radiation Exposure
Enhance and Extend Your Career*

PILOT THE PROCEDURE



Cognitive Skill Elevated

Enhanced environment and information display



Full Control

Control over the entire procedure at
the physician's fingertips



Democratization of Skill

Reduced reliance on hand skill
with focus on therapy



BENEFITS TO HOSPITALS & PAYORS

ARRHYTHMIAS

Widespread



1 in 4 Lifetime Risk of AF
>10-15% Prevalence in Elderly

Undertreated



Demographics: Age & Obesity
Improved Diagnostic Technology

Growing



Poor Anticoagulant Compliance
>30% Undiagnosed AF in Risk Population

Profitable



Highly Reimbursed Procedure
Attractive Patient Demographic

IMPROVED CLINICAL CARE

STRATEGIC DIFFERENTIATION

ATTRACTIVE FINANCIAL ROI



Grow

Treat Complex Arrhythmias
Attract Patients



Reduce Risk


Patient Adverse Events
& Physician Injury



Improved Efficiency

Efficient Staffing
Faster Complex Procedure

GLOBAL PRESENCE & IMPACT




Hundreds of Physicians at 100+ Leading Global Hospitals have Treated 100,000+ Patients



REBUILDING FOR GROWTH



**Financial
Prudence**



**Commercial
Infrastructure**



**Strategic
Innovation**

COMMERCIAL INFRASTRUCTURE



INNOVATION STRATEGY



CORE TECHNOLOGY




Robot



Catheter



X-Ray




Mapping



User Interface



DIGITAL SURGERY



Telemedicine



Automation




Image Guided Therapy



Big Data Insight



BEYOND EP



Endovascular



Endoluminal

Goals:

1

Improve
Patient
Care

2

Enhance
Physician
Experience

3

Increase
Access &
Affordability

4

Create
Collaborative
Open Ecosystem

Recent Innovation Announcements




GENESIS ROBOT & IMAGING

Initiation launch of **Genesis Robotic Magnetic Navigation System**, providing the established benefits of robotics in an architecture that is smaller, lighter, faster and more flexible. Genesis is CE marked and FDA 510k application submitted Nov 2019. Genesis robot launched with tightly-integrated proprietary fluoroscopy system, Stereotaxis Imaging Model S, developed in collaboration with **Omega Medical Imaging**. Designed to improve image quality, reduce radiation, and significantly improve the affordability and availability of robotics.



ABLATION CATHETER

Announced development of an advanced **next-generation robotic ablation catheter**. The catheter, fully owned by Stereotaxis, is being developed in collaboration with **Osypka AG**.




OPEN MAPPING

OpenMapping software architecture implemented to support broad integration of mapping and diagnostic information. Successful integration with AcQMap, an innovative intraoperative mapping system of **Acutus Medical**, announced 1Q 2019. Successful integrations with advanced preoperative maps of **inHeart**, **ADAS3D** and **VIVO** announced 4Q 2019.

INNOVATION DRIVING GROWTH

\$15M
Annual Replacement-Cycle
Revenue Opportunity


5,000+
Electrophysiology labs
performing cardiac ablation



**Robotic
System
Sales**

\$20M+
Incremental Annual Revenue
in Existing Procedure Volume

\$2B+
Increase in Annual Market
Opportunity



**Proprietary
Ablation
Catheter**

\$10B+
Multiple Multi-Billion Dollar
Endovascular & Endoluminal
Markets To Be Addressed



**New
Clinical
Applications**

THANK YOU!

investors@Stereotaxis.com



Innovative Technology

- Highly differentiated approach for endovascular surgery
- Global leadership in endovascular robotics



Proven Clinical Value

- Enables therapy and improves patient outcomes
- Extensive real-world clinical validation



Solid Foundation

- Financial stability: strong balance sheet & near breakeven
- Aligned Board, Management and Shareholders




Strong Growth Drivers

- Large growing existing and future markets
- Pipeline of significant innovation

APPENDIX


The clinical data on the following slides is a comprehensive and objective review of all known publications since 2012 with >50 patients where robotic and manual cardiac ablation were compared in a head-to-head fashion.

Appendix: Major Adverse Events



Major adverse event rates comparing RMN (orange) vs. manual navigation (gray) in head-to-head publications of >50 patients from 2012-2019. Studies which did not report data for major adverse events^{4, 5} or reported no major adverse events in either group^{2, 12, 13, 18} were excluded. AF=Atrial Fibrillation, PVC=Premature Ventricular Contraction, SVT=Supraventricular Tachycardia, VT=Ventricular Tachycardia


Appendix: Fluoroscopy Reduction



Average reduction in patient fluoroscopy exposure comparing RMN (orange) vs. manual navigation in head-to-head publications of >50 patients from 2012-2019. Studies which did not report fluoroscopy exposure data were excluded.^{7, 8, 9}

AF=Atrial Fibrillation, AP= Accessory Pathway-Mediated Tachycardia, PVC=Premature Ventricular Contraction, SVT=Supraventricular Tachycardia, VT=Ventricular Tachycardia

Appendix: Acute Efficacy




Acute success rates comparing RMN (orange) vs. manual navigation (gray) in head-to-head publications of >50 patients from 2012-2019.

Studies which did not report acute success data were excluded.^{6, 8, 9, 10, 11, 15}

AF=Atrial Fibrillation, AP= Accessory Pathway-Mediated Tachycardia, PVC=Premature Ventricular Contraction, SVT=Supraventricular Tachycardia, VT=Ventricular Tachycardia

Appendix: Long Term Efficacy



Freedom from recurrence rates comparing RMN (orange) vs. manual navigation (gray) in head-to-head publications of >50 patients from 2012-2019 with follow-up greater than or equal to one year.

Studies which reported follow-up of less than one year^{4, 13} or did not report freedom from recurrence data^{7, 8, 14} were excluded.

AF=Atrial Fibrillation, AP= Accessory Pathway-Mediated Tachycardia, PVC=Premature Ventricular Contraction, SVT=Supraventricular Tachycardia, VT=Ventricular Tachycardia

References

1. Szili-Torok T, Schwagten B, Akca F, Bauernfeind T, Abkenari LD, Haitsma D, et al. Catheter ablation of ventricular tachycardias using remote magnetic navigation: a consecutive case-control study. *J Cardiovasc Electrophysiol.* 2012;23(9):948-54.
2. Kim JJ, Macicek SL, Decker JA, Kertesz NJ, Friedman RA, Cannon BC. Magnetic versus manual catheter navigation for ablation of free wall accessory pathways in children. *Circ Arrhythm Electrophysiol.* 2012; 2012;5:804-8.
3. Dinov B, Schönbauer R, Wojdyla-Hordynska A, Braunschweig F, Richter S, Altmann D, et al. Long-term efficacy of single procedure remote magnetic catheter navigation for ablation of ischemic ventricular tachycardia: a retrospective study. *J Cardiovasc Electrophysiol.* 2012;23(5):499-505.
4. Roudijk RW, Gujic M, Suman-Horduna I. Catheter ablation in children and young adults: is there an additional benefit from remote magnetic navigation? *Net Heart J.* 2013;21:296–303.
5. Akca F, Theuns DAMJ, Dabiri Abkenari L, de Groot NMS, Jordaens L, Szili-Torok T. Outcomes of repeat catheter ablation using magnetic navigation or conventional ablation. *EP Europace.* 2013;15(10):1426-31.
6. Koutalas E, Bertagnolli L, Sommer P, Richter S, Rolf S, Breithardt O, et al. Efficacy and safety of remote magnetic catheter navigation vs. manual steerable sheath-guided ablation for catheter ablation of atrial fibrillation: a case-control study. *Europace.* 2015;17(2):232-8.
7. Hendriks AA, Akca F, Dabiri Abkenari L, Khan M, Bhaqwandien R, Yap SC, et al. Safety and clinical outcome of catheter ablation of ventricular arrhythmias using contact force sensing: consecutive case series. *J Cardiovasc Electrophysiol.* 2015;26(11):1224-9.
8. Akca F, Janse P, Theuns DA, and Szili-Torok T. A prospective study on safety of catheter ablation procedures: contact force guided ablation could reduce the risk of cardiac perforation. *Int J Cardiol.* 2015;179:441-8.
9. Di Biase L, Tung R, Burkhardt JD, Romero J, Trivedi C, Mohanty S, et al. Scar homogenization ablation in patients with ischemic cardiomyopathy: comparison between remote magnetic navigation and manual ablation. *Circulation.* 2015;132 Suppl 3.
10. Weiss JP, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, et al. A Comparison of Remote Magnetic Irrigated Tip Ablation versus Manual Catheter Irrigated Tip Catheter Ablation With and Without Force Sensing Feedback. *J Cardiovasc Electrophysiol.* 2016;27 Suppl 1:S5-S10.
11. Adragão PP, Cavaco D, Ferreira AM, Costa FM, Parreira L, Carmo P, et al. Safety and Long-Term Outcomes of Catheter Ablation of Atrial Fibrillation Using Magnetic Navigation versus Manual Conventional Ablation: A Propensity-Score Analysis. *J Cardiovasc Electrophysiol.* 2016;27 Suppl 1:S11-6.
12. Kawamura M, Scheinman MM, Tseng ZH, Lee BK, Marcus GM, Badhwar N. Comparison of remote magnetic navigation ablation and manual ablation of idiopathic ventricular arrhythmia after failed manual ablation. *J Interv Card Electrophysiol.* 2017;48(1):35-42.
13. Reents T, Jilek C, Schuster P, Nölker G, Koch-Büttner K, Ammar-Busch S, et al. Multicenter, randomized comparison between magnetically navigated and manually guided radiofrequency ablation of atrioventricular nodal reentrant tachycardia (the MagMa-AVNRT-trial). *Clin Res Cardiol.* 2017;106(12):947-52.
14. Lim PCY, Toh JJH, Loh J, Lee ECY, Chong DTT, Tan BY, et al. Remote magnetic catheter navigation versus conventional ablation in atrial fibrillation ablation: Fluoroscopy reduction. *J Arrhythm.* 2017;33(3):167-71.
15. Yuan S, Holmqvist F, Kongstad O, Jensen SM, Wang L, Ljungström E, et al. Long-term outcomes of the current remote magnetic catheter navigation technique for ablation of atrial fibrillation. *Scand Cardiovasc J.* 2017;51(6):308-15.
16. Kataria V, Berte B, Vandekerckhove Y, Tavernier R, and Duytschaever M. Remote Magnetic versus Manual Navigation for Radiofrequency Ablation of Paroxysmal Atrial Fibrillation: Long-Term, Controlled Data in a Large Cohort. *Biomed Res Int.* 2017;2017:6323729.
17. Qiu X, Zhang N, Luo Q, Liu A, Ji Y, Ye J, et al. Remote magnetic navigation facilitates the ablations of frequent ventricular premature complexes originating from the outflow tract and the valve annulus as compared to manual control navigation. *Int J Cardiol.* 2018;267:94-99.
18. Parreira L, Marinheiro R, Carmo P, Cavaco D, Reis-Santos K, Amador P, et al. Atrioventricular node reentrant tachycardia: Remote magnetic navigation ablation versus manual ablation – impact on operator fluoroscopy time. *Revista Portuguesa de Cardiologia.* 2019;38(3):187-192.